Greater Cannabis Overhauls Board and Management, Plans Name Change and 1-for-5 Reverse Split
GCAN has more than doubled off its 52-week low of $0.036.
Summary
Greater Cannabis Company appointed three new directors and executive officers from controlling shareholder Trafalgar Asset Management, changed its name to Trafalgar International, and approved a 1-for-5 reverse stock split — completing a full operational takeover and strategic pivot.
Key Events · Executive and Board Changes · GCAN
-
New Board and Management Installed
Carlos Septién has been appointed COO and director, Michelle Cervantes Vivanco CFO and director, and Ernesto Gómez Berjón Chief Growth Officer and director — all hailing from Trafalgar Asset Management, which secured 96.62% voting control on July 6, 2026.
-
Corporate Name Change
The company will be renamed Trafalgar International, Inc., underscoring the departure from cannabis and the pivot toward Trafalgar's financial services operations.
-
1-for-5 Reverse Stock Split Approved
Every five shares of Common Stock will be combined into one share, with fractional shares rounded up. The authorized share count and Preferred Stock terms remain unchanged.
-
Amended and Restated Bylaws Adopted
New bylaws, effective immediately, modernize governance provisions and reflect the incoming management structure.
Analysis · GCAN · Life Sciences
A completely new leadership team from Trafalgar Asset Management, which took control earlier this month, is being installed. Three new directors are joining the board — including a COO, CFO, and Chief Growth Officer — cementing Trafalgar's operational grip. At the same time, the company is changing its name to Trafalgar International and executing a 1-for-5 reverse stock split. These actions signal a full strategic pivot away from cannabis and toward Trafalgar's financial services focus. For a micro-cap company in severe financial distress, the reverse split is a survival tactic to maintain listing eligibility, but it also concentrates risk for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCAN was trading at $0.22 on OTC in the Life Sciences sector, with a market capitalization of approximately $218.8K. The 52-week trading range was $0.04 to $3.60. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.